B. Riley Securities Maintains Buy on Unicycive Therapeutics, Maintains $22 Price Target
B. Riley Securities analyst Mayank Mamtani maintains Unicycive Therapeutics (NASDAQ: UNCY ) with a Buy and maintains $22 price target.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.